stage 2, metabolic risk factors (those with hypertension, hypertriglyceridemia, metabolic syndrome, or type 2 diabetes mellitus) or early CKD
February 2025: Novo Nordisk announced that semaglutide 2.4 mg would be available in Mexican pharmacies by April 2025, with an average 17.5% weight loss observed in pivotal trials
Once depleted, it turns to fatty acids
Hormonal factors affect maintenance
The SURMOUNT trials reported that approximately 4 to 7% of participants discontinued due to adverse events, depending on dose level
The name reflects both the skin improvements users report and the acronym-adjacent grouping of Growth (GHK-Cu), Localized healing (BPC-157), and Overall repair (TB-500 and Wolverine)